Literature DB >> 10022244

The CD95(APO-1/Fas)/CD95L system.

P H Krammer1.   

Abstract

The CD95 system is one of the best studied death systems and plays an essential role in the immune system, particularly in deletion of peripheral T-cells and in homeostasis of the liver. Here genetic defects in the CD95 system are discussed as well as recent findings of the CD95 signalling pathway.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 10022244     DOI： 10.1016/s0378-4274(98)00297-5

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN： 0378-4274            Impact factor:   4.372


  8 in total

Review 1.  Caspases: pharmacological manipulation of cell death.

Authors:  Inna N Lavrik; Alexander Golks; Peter H Krammer
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Effects of Shenqi Fuzheng injection on Fas/FasL protein expression levels in the cardiomyocytes of a mouse model of viral myocarditis.

Authors:  Tianmin Wu; Jinshui Chen; Liufang Fan; Wenyan Xie; Changsheng Xu; Huajun Wang
Journal:  Exp Ther Med       Date:  2016-03-15       Impact factor: 2.447

3.  The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.

Authors:  Ramazan Yildiz; Mustafa Benekli; Suleyman Buyukberber; Ali Osman Kaya; Banu Ozturk; Emel Yaman; Veli Berk; Ugur Coskun; Deniz Yamac; Banu Sancak; Aytug Uner
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-13       Impact factor: 4.553

Review 4.  TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

Authors:  R K Srivastava
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

5.  Role of Programmed Cell Death in the Immunopathogenesis of Sepsis.

Authors:  Mario Perl; Chun-Shiang Chung; Ryan Swan; Alfred Ayala
Journal:  Drug Discov Today Dis Mech       Date:  2007

6.  ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.

Authors:  Jie Yang; Chunxu Yang; Shimin Zhang; Zijie Mei; Mingjun Shi; Shaoxing Sun; Liu Shi; Zhihao Wang; Yacheng Wang; Zhenzhen Li; Conghua Xie
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

7.  Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers.

Authors:  Uddin Md Nazim; Mohammad Rasheduzzaman; You-Jin Lee; Dai-Wu Seol; Sang-Youel Park
Journal:  Oncotarget       Date:  2017-03-14

Review 8.  Main roads to melanoma.

Authors:  Giuseppe Palmieri; Mariaelena Capone; Maria Libera Ascierto; Giusy Gentilcore; David F Stroncek; Milena Casula; Maria Cristina Sini; Marco Palla; Nicola Mozzillo; Paolo A Ascierto
Journal:  J Transl Med       Date:  2009-10-14       Impact factor: 5.531
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.